arrow
J

Jacob J. Orme

Mayo Clinic
H指数:19
被引数:1,326

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

LuRa: Efficacy and Safety of Radium-223 Following [177Lu]Lu-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate Cancer

LuRa:Radium-223在转移性去势抵抗性前列腺癌患者中继[177Lu]Lu-PSMA-617后的疗效与安全性

2026-06-010
PRE
A PELVIC MRI FOR BIOCHEMICAL RECURRENCE OF PROSTATE CANCER AFTER RADICAL PROSTATECTOMY STRATIFIES OUTCOMES FOR SALVAGE RADIATION VS OBSERVATION

根治性前列腺切除术后前列腺癌生化复发患者盆腔MRI对挽救性放疗与观察治疗的预后分层

2026-05-010
PRE
Outcomes of stereotactic body radiotherapy for supraclavicular lymph node metastasis among patients with metastatic prostate cancer

锁骨上淋巴结转移的转移性前列腺癌患者立体定向体部放射治疗的结局

2026-04-130
OAAI
PSA Zero Radiographic Disease Progression on PSMA PET/CT

PSA零放射学疾病进展(在PSMA PET/CT上)

Cancers
IF4.4
2026-03-040
OAAI
Molecular Landscape of Prostate Cancers with Clival Metastases

伴有蝶骨转移的前列腺癌的分子景观

2026-03-040
OA
Reversing enhancer RNA-mediated IKBKE gene repression enables synthetic anticancer immunity in prostate cancer models

通过逆转增强子RNA介导的IKBKE基因抑制,在前列腺癌模型中实现合成抗癌免疫

2026-01-161
PRE
Comparative Survival in Metastatic Hormone-sensitive Prostate Cancer by Volume of Disease and Timing of Metastasis: A Living Network Meta-analysis

比较性生存分析:激素敏感性转移性前列腺癌按疾病体积和转移时间划分——一项动态网络Meta分析

2025-11-040
PRE
Defining NECTIN4 Amplification and Protein Expression in Urothelial Carcinoma and Histologic Subtypes

定义尿路上皮癌及其组织学亚型中NECTIN4扩增和蛋白质表达

2025-10-290
OAAI
Development and External Validation of a Local Pelvic Recurrence Risk Score After Radical Cystectomy: Identifying the Ideal Candidate for Adjuvant Radiation Clinical Trials

根治性膀胱切除术后局部盆腔复发风险评分的开发与外部验证:识别辅助放疗临床试验的理想人选

2025-10-010
PRE
BELZUTIFAN IN CLINICAL PRACTICE: OUTCOMES AND SAFETY IN A REAL-WORLD COHORT OF PATIENTS WITH VHL-ASSOCIATED NEOPLASMS

贝尔祖替凡在临床实践中的应用:VHL相关肿瘤患者真实世界队列的疗效与安全性

2025-10-010
OA
Evolution of Potentially Actionable Genomic Alterations in Advanced Prostate Cancer: A Real-World Analysis of Serial Circulating Tumor DNA Testing

晚期前列腺癌中潜在可操作基因组改变的演变:基于连续循环肿瘤DNA检测的真实世界分析

CANCERS
IF4.4
2025-09-180
OAAI
Outcomes for [177Lu]Lu-PSMA-617 with and Without Concurrent Use of Androgen Receptor Pathway Inhibitors in Patients with Metastatic Castration-resistant Prostate Cancer

[177Lu]Lu-PSMA-617在有和无雄激素受体通路抑制剂联合使用情况下,在转移性去势抵抗性前列腺癌患者中的疗效

2025-08-050
PRE
[177Lu] Lu-PSMA-617 treatment for metastatic castration-resistant prostate cancer (mCRPC) with cerebral and cerebellar metastases

[177Lu] Lu-PSMA-617治疗伴有脑部和脑桥部转移的转移性去势抵抗性前列腺癌(mCRPC)

2025-07-210
PRE
Consolidative Surgery for Advanced Urothelial Carcinoma Following Induction Enfortumab Vedotin and/or Immune Checkpoint Inhibitor Therapy: A Multicenter Analysis

对接受诱导恩沃夫妥单抗和/或免疫检查点抑制剂治疗后进展的尿路上皮癌进行巩固性手术的多中心分析

2025-05-260
PRE